Vivek Ramaswamy, the founder of Roivant Sciences, is considering a bid for the Republican presidential nomination, according to a report by POLITICO Monday.

Myovant Sciences agreed to be acquired by Sumitovant Biopharma for $2.9 billion – three weeks after turning down a previous offer.

Myovant Sciences announced Sunday it formed a special committee of independent directors to assess Sumitovant Biopharma’s offer to acquire the company, and ultimately, turned the offer down.